Semi-synthetic heparinoids

Handbook of Experimental Pharmacology

Volumn 207, Issue , 2012, Pages 403-422

  Oreste, P ^a   Zoppetti, G ^a  

^a Glycores 2000 Srl   (Italy)

Author keywords

AIDS; Angiogenesis; Cell proliferation; Heparin from K5 polysaccharide; Herpes simplex virus; HIV 1; Inflammation; K5 polysaccharide; K5 polysaccharide derivatives; Papillomavirus

Indexed keywords

BACTERIAL POLYSACCHARIDE; EPIMERASE; FIBROBLAST GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HEPARINOID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; K5 POLYSACCHARIDE; LOW MOLECULAR WEIGHT HEPARIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; POLYSACCHARIDE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CYTOKINE PRODUCTION; DEACETYLATION; DEAMINATION; DISSOCIATION CONSTANT; DRUG DECOMPOSITION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SULFATION; DRUG SYNTHESIS; EPIMERIZATION; ESCHERICHIA COLI; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; THROMBOEMBOLISM; VIRUS ATTACHMENT; ANIMAL; CHEMISTRY; REVIEW; SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HEPARINOIDS; HUMANS; POLYSACCHARIDES;

EID: 84861884600     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-23056-1_18     Document Type: Article

References (89)

1. Adamiak B, Ekblad M, Bergstr€om T, Ferro V, Trybala E (2007) Herpes simplex virus type 2 glycoprotein G is targeted by the sulfated oligo- and polysaccharide inhibitors of virus attachment to cells. J Virol 81:13424-13434
2. 2+: A model study with a synthetic heparin-like hexasaccharide. Isr J Chem 40:289-299
3. Arduino PG, Porter SR (2008) Herpes simplex virus type 1 infection: Overview on relevant clinicopathological features. J Oral Pathol Med 37:107-121
4. Attanasio M, Gori AM, Giusti B, Pepe C, Comeglio P, Brunelli T, Prisco D, Abbate R, Gensini GF, Neri Serneri GG (1998) Cytokines gene expression in human LPS- and IFNg-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 79:959-962
5. Ayotte L, Perlin AS (1986) N.M.R. spectroscopic observations related to the function of sulfate groups in heparin. Calcium binding vs. biological activity. Carbohydr Res 145:267-277
6. Barrowcliffe TW (1989) The anticoagulant activity of heparin: measurement and relationship to chemical structure. J Pharm Biomed Anal 7:217-226
7. Basilico C, Moscatelli D (1992) The FGF family of growth factors and oncogenes. Adv Cancer Res 59:115-165
8. Bjõrk I, Lindahl U (1982) Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 48:161-182
9. Borgenstr€om M, Jalkanen M, Salmivirta M (2003) Sulfated derivatives of Escherichia coli K5 polysaccharide as modulators of fibroblast growth factor signalling. J Biol Chem 278: 49882-49889
10. Bosch FX, de Sanjose S (2003) Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31:3-13
11. Campbell P, Hannessonn HH, Sandbäck D, Rodén L, Lindahl U, Li J-P (1994) Biosynthesis of heparin/heparan sulfate. Purification of the D-glucuronyl C-5 epimerase from bovine liver. J Biol Chem 268:26953-26958
12. Caputo A, Boarini BM, Mantovani I, Corallini A, Barbanti-Brodano G (1999) Multiple functions of human immunodeficiency virus type 1 Tat protein in the pathogenesis of AIDS. Virology 1:753-778
13. Casu B, Grazioli G, Hannessonn HH, Jann B, Jann K, Lindahl U, Naggi A, Oreste P, Razi N, Torri G, Tursi F, Zoppetti G (1994a) Biologically active, heparan sulfate-like species by combined chemical and enzymic modification of the Escherichia coli polysaccharide K5. Carbohydr Lett 1:107-114
14. Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, Oreste P, Tursi F, Zoppetti G, Lindahl U (1994b) Heparin-like compounds prepared by chemical modification of capsular polysaccharide from Escherichia coli K5. Carbohydr Res 263:271-284
15. Cavazzoni V, Manzoni M, Bergomi S (1992) Production and characterization of the Escherichia coli K5 polysaccharide in the extracellular form. Ann Microbiol Enzymol 42:101-110
16. Cheshenko N, Keller MJ, MasCasullo VG, Jarvis A, Cheng H, John M et al (2004) Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cellto- cell spread. Antimicrob Agents Chemother 48:2025-2036
17. Chess EK et al (2011) Case study: Contamination of heparin with oversulfated chondroitin sulfate. In: Lever R, Mulloy B, Page CP (eds) Heparin - a century of progress. Springer, Heidelberg Choay J (1989) Structure and activity of heparin and its fragments: An overview. Semin Thromb Hemost 15:359-364
18. Choay J, Lormeau J-C, Petitou M, Sinay P, Casu B, Oreste P, Torri G, Gatti G (1980) Anti-Xa active heparin oligosaccharides. Thromb Res 18:573-578
19. Corey L, Wald A (1999) Genital herpes. In: Holmes KK, Sparling PF, Mardh PA et al (eds) Sexually transmitted diseases. McGraw-Hill, New York, pp 285-312
20. De Clercq E (1989) Potential drugs for treatment of AIDS. J Antimicrob Chemoter 23(Suppl A): 35-46
21. Dewhurst S, Gelbard HA, Fine SM (1996) Neuropathogenesis of AIDS. Mol Med Today 2:16-23
22. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY (1999) FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 18:2755-2761
23. Engelberg H (1999) Actions of heparin that may affect the malignant process. Cancer 85:257-272
24. Ferro DR, Provasoli A, Ragazzi M, Casu B, Torri G, Bossenec V, Perly B, Sinay P, Petitou M, Choay J (1990) Conformer populations of L-Iduronic acid residues in glycosaminoglycans sequences. Carbohydr Res 195:157-167
25. Freeman EE, Weiss HA, Glynn JR, Cross PL, Withworth JA, Hayes RJ (2006) Herpes symplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 20:73-83
26. Gatignol A, Jeang KT (2000) Tat as a transcriptional activator and a potential therapeutic target for HIV-1. In: Jeang KT (ed) Advances in pharmacology, vol 48. Academic Press, San Diego, CA, pp 209-227
27. Giroglou T, Florin L, Sh€afer F, Streek RE, Sapp M (2001) Human papillomavirus infection requires cell surface heparan sulphate. J Virol 75:1565-1570
28. Goldstein G (1996) HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 2:960-964
29. Gori AM, Attanasio M, Gazzini A, Rossi L, Lucarini L, Miletti S, Chini J, Manoni M, Abbate R, Genuini GF (2004) Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives. J Thromb Haemost 2:1657-1662
30. Hagner-McWhirter A, Hannessonn HH, Campbell P, Westley J, Rodén L, Lindahl U, Li J-P (2000) Biosynthesis of heparin/heparan sulfate: kinetic studies of the glucuronyl C5-epimerase with N-sulfated derivatives of the Escherichia coli K5 capsular polysaccharide as substrates. Glycobiology 10:159-171
31. Harrop HA, Coombe DR, Rider CC (1994) Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS 8:183-192
32. Herold BC, Gerber SI, Belval BJ, Siston AM, Shulman N (1996) Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J Virol 70:3461-3469
33. Ishihara M, Tyrrell DJ, Stauber GB, Brown S, Counses LS, Stack RJ (1993) Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 268:4675-4683
34. Jacobsson I, Lindahl U, Jensen JW, Rodén L, Prihar H, Feingold DS (1984) Biosynthesis of heparin - substrate specificity of heparosan N-sulfate d-glucuronosyl 5-epimerase. J Biol Chem 259:1056-1063
35. Jann B, Jann K (1990) Structure and biosynthesis of the capsular antigens of Escherichia coli, vol 150, Current topics in microbiology and immunology. Springer, Heidelberg, pp 19-42
36. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM (1999) HPV: from infection to cancer. J Biol Chem 274:5810-5822
37. Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS (2007) Surface-exposed aminoacids of HPV16L1 protein mediating interaction with cell surface heparan sulphate. J Biol Chem 282:27913-27922
38. Kusche M, Hannesson H, Lindahl U (1991) Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions. Biochem J 275:151-158
39. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M (2001) Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 276:37900-37908
40. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements D et al (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74:38-45
41. Lembo D, Donalisio M, Rusnati M, Bugatti A, Cornaglia M, Cappello P, Giovarelli M, Oreste P, Landolfo S (2008) Sulfated K5 Escherichia Coli polysaccharide derivatives as widerange inhibitors of genital types of human papillomavirus. Antimicrob Agents Chemother 52: 1374-1381
42. Li J-P, Hagner-McWhirter A , Kjellen L, Palgi J, Jalkanen M, Lindahl U (1997) Biosynthesis of heparin/heparan sulfate. cDNA cloning and expression of D-glucuronyl C5 epimerase from bovine lung. J Biol Chem 272:28158-28163
43. Liang JN, Chakrabarti B, Ayotte L, Perlin AS (1982) An essential role for the 2-sulfamino group in the interaction of calcium ion with heparin. Carbohydr Res 106:101-109
44. Lindahl U, Bäckström G, Thunberg L, Leder IG (1980) Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 77:6551-6555
45. Lindahl U, Kusche M, Lidholt K, Oscarsson L-G (1989) Biosynthesis of heparin and heparan sulphate. Ann NY Acad Sci 556:36-50
46. Lowry DR, Howley PM (2001) Papillomaviruses. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 2231-2264
47. Maccarana M, Tawada A, Yoshida K, Lindahl U (1996) Domain structure of heparan sulfates from bovine organs. J Biol Chem 271:17804-17810
48. Malmström A, Rodén L, Feingold DS, Jacobsson I, Bäckström G, Lindahl U (1980) Biosynthesis of heparin. Partial purification of the uronosyl C-5 epimerase. J Biol Chem 255:3878-3883
49. Manzoni M, Bergomi S, Cavazzoni V (1993) Extracellular K5 polysaccharide of Escherichia coli: production and characterization. J Bioact Compat Polym 8:251-259
50. Manzoni M, Bergomi S, Cavazzoni V (1996) Production of K5 polysaccharides of different molecular weight by Escherichia coli. J Bioact Compat Polym 11:301-311
51. Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D (1999) Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 18:1053-1060
52. McGrath BJ, Newman CI (1994) Genital herpes simplex infections in patients with the acquired immunodeficiency syndrome. Pharmacotherapy 14:529-542
53. McKeehan WL, Wang F, Kan M (1998) The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acids Res Mol Biol 59:135-176
54. Moore JP, StevensonM(2000) New targets for inhibitors of HIV-1 replication. RevMol Cell Biol 1: 40-49
55. Naggi A, Torri G, Casu B, Oreste P, Zoppetti G, Li J-P, Lindahl U (2001) Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost 27:437-443
56. Ogamo A, Metori A, Ukiyama N (1989) Reactivity toward chemical sulfation of hydroxyl groups of heparin. Carbohydr Res 193:165-172
57. Oreste P, Zoppetti G (2000) Glycosaminoglycans derived from K5 polysaccharide having high antithrombin activity and process for their preparation. EP01271394.7
58. Oreste P, Zoppetti G (2002a) Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation. US 2002/0062019
59. Oreste P, Zoppetti G (2002b) Highly sulfated derivatives of K5 polysaccharide and their preparation. EP1366082
60. Oreste P, Zoppetti G (2003a) Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation. EP1513880
61. Oreste P, Zoppetti G (2003b) Low molecular polysaccharides having antithrombin activity. EP1694714
62. Oreste P, Zoppetti G (2003c) Process for the manufactiurer of N-acyl-(epi)K5-amine-O-sulfatederivatives and product thus obtained. US 12/120,167
63. Ørskov I, Ørskov F, Jann B, Jann K. 1977 Serology, chemistry, and genetics of O and K antigens of Escherichia coli Bacteriol Rev 41 3 667-710
64. Petitou M, Duchaussoy P, Lederman I, Choay J, Jacquinet JC, Sinay P, Torri G (1987) Synthesis of heparin fragments: A methyl-α pentaoside with high affinity for antithrombin III. Carbohydr Res 167:67-75
65. Petitou M, Lormeau JC, Choay J (1988) Interaction of heparin and antithrombin III. The role of O-sulfate groups. Eur J Biochem 176:637-640
66. Pinna D, Oreste P, Coradin T, Kajaste-Rudnisti A, Ghezzi S, Zoppetti G, Rotola A, Argnani R, Poli G, Manservigi R, Vicenzi E (2008) Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia Coli K5 polysaccharide. Antimicrob Agents Chemother 52:3078-3084
67. Presta M, Oreste P, Zoppetti G, Belleri M, Vanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Vicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D (2005) Antiangiogenetic activity of semisynthetic biotechnological heparins. Low molecular weight-sulfated Escherichia coli polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol 25:71-76
68. Razi N, Feyzi E, Björk I, Naggi A, Casu B, Lindahl U (1995) Structural and functional properties of heparin analogs obtained by chemical sulphation of E. coli K5 capsular polysaccharide. Biochem J 270:11267-11275
69. Rider CC (1997) The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection. Glycoconj J 14:639-642
70. Rider CC, Coombe DR, Harrop HA, Hounsell EF, Bauer C, Feeney J et al (1994) Anti-HIV-1 activity of chemically modified heparins: Correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33:6974-6980
71. Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, Giacca M, Ciompi M, Corallini A, Presta M (1998) The basic domain in HIV-1 Tat protein as a target for polysulfonated heparinmimicking extracellular Tat antagonists. J Biol Chem 273:16027-16037
72. Rusnati M, Tulipano G, Spillmann D, Vanghetti E, Oreste P, Zoppetti G, Giacca M, Presta M (1999) Multiple interaction of HIV-1 Tat protein with sized-defined heparin oligosaccharides. J Biol Chem 274:28198-29205
73. Rusnati M, Oreste P, Zoppetti G, Presta M (2005) Biotechnological engineering of heparin/ heparan sulphate: A novel area of multi-target drug discovery. Curr Pharm Des 11:2489-2499
74. Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D (2009) Sulfated K5 Escherichia Coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. Pharmacol Ther 123:310-322
75. Schlessinger J, Lax I, LemmonM(1995) Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? Cell 83:357-360
76. Shafti-Keramat S, Handisurya A, Kriehuber E, Menguzzi G, Slupetzky K, Kirnbauer R (2003) Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77:13125-13135
77. Shukla D, Spear PG (2001) Herpesviruses and heparan sulfate: An intimate relationship in aid of viral entry. J Clin Invest 108:503-510
78. Thunberg L, Bäckström G, Lindahl U (1982) Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 100:393-410
79. Tyagi M, Rusnati M, Presta M, Giacca M(2001) Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276:3254-3261
80. Urbinati C, Bugatti A, Oreste P, Zoppetti G, Waltenberger J, Mitola S, Ribatti D, Presta M, Rusnati M (2004) Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett 568:171-177
81. Van Boeckel CAA, van Aelst SF, Wanegaars GN, Mellema JR (1987) Conformational analysis of synthetic heparin-like oligosaccharides containing α-L-idopyranosiluronic acid. Recl Trav Chim Pays Bas 106:19-29
82. Vann F, Schmidt MA, Jann B, Jann K (1981) The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. Eur J Biochem 116:359-364
83. Vicenzi E, Gatti A, Ghezzi S, Oreste P, Zoppetti G, Poli G (2003) Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia Coli polysaccharide derivatives. AIDS 17: 177-181
84. Viskov C, Lux F, Gervier, R, Colas G (2006) Method for producing K5 polysaccharide. WO 2006/ 030099
85. Vives RR, Imberty A, Sattentau Q, Lortat-Jacob H (2005) Heparan sulfate targets the HIV-1 envelope glycoprotein gp 120 coreceptor binding site. J Biol Chem 22:21353-21357
86. von Tempelhoff GF, Heilmann L (2000) Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematol Oncol Clin North Am 14:1151-1169
87. Whitfield DM, Sakar B (1991) Metal binding to heparin monosaccharides: D-glucosamine- 6-sulphate, D-glucuronic acid and L-iduronic acid. J Inorg Biochem 41:157-170
88. Whitley RJ, Roizman B (2001) Herpes simplex virus infections. Lancet 357:1513-1518
89. Zacharski LR, Ornstein DL, Mamourian AC (2000) Low-molecular-weight heparin and cancer. Semin Thromb Hemost 26:69-77